CatalystFDA/Bio

CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE; NOTICE OF MEETING; ESTABLISHMENT OF A PUBLIC DOCKET; REQUEST FOR COMMENTS-BIOLOGICS LICENSE APPLICATION (BLA) 125827, FROM REPLIMUNE, INC. FOR

BLA filing and advisory committee meeting signal potential regulatory catalyst for Replimune product.

What changed

BLA filing and advisory committee meeting signal potential regulatory catalyst for Replimune product.

Why it matters

BLA filing and advisory committee meeting signal potential regulatory catalyst for Replimune product. — impact context not separately stored; see What changed.

Sources

federalregister